Neurent Medical obtains FDA Clearance for NEUROMARK™, a novel multi-point Nerve Disruption Treatment for Chronic Rhinitis
On November 18, 2021, Neurent Medical, a company working in developing treatments for chronic inflammatory sino-nasal diseases, received clearance from the Food and Drug Administration (FDA) for its proprietary NEUROMARK™ Rhinitis Neurolysis Therapy™ (RNT). This will provide clinicians access to an in-office treatment intended to develop lesions to disrupt the posterior nasal nerves for chronic rhinitis patients.
Marc Dubin, MD, Scientific Advisor for Neurent Medical, said that the FDA clearance of NEUROMARK&#...
